Citadel Advisors’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $95M | Sell |
974,911
-635,572
| -39% | -$55.5M | 0.01% | 1007 |
|
|
2026
Q1 | $135M | Buy |
1,610,483
+541,549
| +51% | +$31.4M | 0.02% | 636 |
|
|
2025
Q4 | $44.1M | Buy |
1,068,934
+55,433
| +5% | +$2.15M | 0.01% | 1540 |
|
|
2025
Q3 | $39.9M | Buy |
1,013,501
+348,457
| +52% | +$8.91M | 0.01% | 1606 |
|
|
2025
Q2 | $12.4M | Buy |
665,044
+194,164
| +41% | +$3.64M | ﹤0.01% | 2738 |
|
|
2025
Q1 | $8.54M | Buy |
470,880
+48,842
| +12% | +$1.08M | ﹤0.01% | 3068 |
|
|
2024
Q4 | $9.2M | Buy |
422,038
+362,737
| +612% | +$9.33M | ﹤0.01% | 3092 |
|
|
2024
Q3 | $1.62M | Buy |
+59,301
| New | +$1.65M | ﹤0.01% | 5902 |
|
|
2024
Q2 | – | Sell |
-24,829
| Closed | -$745K | – | 14457 |
|
|
2024
Q1 | $745K | Buy |
+24,829
| New | +$540K | ﹤0.01% | 7532 |
|
|
2023
Q4 | – | Sell |
-105,561
| Closed | -$1.44M | – | 14447 |
|
|
2023
Q3 | $1.44M | Sell |
105,561
-104,439
| -50% | -$1.32M | ﹤0.01% | 5839 |
|
|
2023
Q2 | $2.55M | Buy |
210,000
+209,449
| +38,013% | +$2.38M | ﹤0.01% | 4737 |
|
|
2023
Q1 | $7.01K | Buy |
551
+62
| +13% | +$686 | ﹤0.01% | 13763 |
|
|
2022
Q4 | $3.09K | Sell |
489
-2,027
| -81% | -$35.9K | ﹤0.01% | 14251 |
|
|
2022
Q3 | $56K | Buy |
+2,516
| New | +$68.9K | ﹤0.01% | 11538 |
|
|
2022
Q2 | – | Sell |
-8,750
| Closed | -$406K | – | 13088 |
|
|
2022
Q1 | $406K | Buy |
+8,750
| New | +$478K | ﹤0.01% | 9863 |
|
|
2021
Q3 | – | Sell |
-8,642
| Closed | -$1.01M | – | 13928 |
|
|
2021
Q2 | $1.35M | Sell |
8,642
-39,821
| -82% | -$7.31M | ﹤0.01% | 7563 |
|
|
2021
Q1 | $9.18M | Buy |
48,463
+42,174
| +671% | +$7.1M | ﹤0.01% | 3103 |
|
|
2020
Q4 | $789K | Buy |
6,289
+1,634
| +35% | +$185K | ﹤0.01% | 7282 |
|
|
2020
Q3 | $506K | Sell |
4,655
-755
| -14% | -$89.5K | ﹤0.01% | 7277 |
|
|
2020
Q2 | $650K | Sell |
5,410
-1,421
| -21% | -$200K | ﹤0.01% | 6606 |
|
|
2020
Q1 | $686K | Buy |
6,831
+1,340
| +24% | +$248K | ﹤0.01% | 5957 |
|
|
2019
Q4 | $1.33M | Sell |
5,491
-5,791
| -51% | -$1.08M | ﹤0.01% | 5073 |
|
|
2019
Q3 | $1.85M | Sell |
11,282
-3,035
| -21% | -$577K | ﹤0.01% | 4595 |
|
|
2019
Q2 | $3.38M | Buy |
14,317
+3,428
| +31% | +$848K | ﹤0.01% | 3675 |
|
|
2019
Q1 | $2.87M | Buy |
10,889
+9,546
| +711% | +$1.65M | ﹤0.01% | 3840 |
|
|
2018
Q4 | $122K | Buy |
+1,343
| New | +$183K | ﹤0.01% | 8160 |
|
|
2018
Q3 | – | Sell |
-5,425
| Closed | -$1.17M | – | 9288 |
|
|
2018
Q2 | $1.17M | Buy |
+5,425
| New | +$1.22M | ﹤0.01% | 4943 |
|
Other funds holding DNTH
FFM
APM
OCA
Citadel Advisors's DNTH Position: Q2 2026 in Review
Citadel Advisors reduced its Dianthus Therapeutics (DNTH) stake by 39% in Q2 2026, selling an estimated $55.5M and leaving 974,911 shares worth $95M. The position accounts for 0.01% of the portfolio, ranked #1007.
Citadel Advisors first reported a position in DNTH in Q2 2018 and has held it in 27 quarters since. The position peaked at $135M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Citadel Advisors held 974,911 shares of Dianthus Therapeutics worth $95M as of Q2 2026.
- Citadel Advisors sold 635,572 Dianthus Therapeutics shares in Q2 2026, an estimated $55.5M.
- Dianthus Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1007 holding.
- Citadel Advisors first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 27 quarters since.
- Citadel Advisors's Dianthus Therapeutics position peaked at $135M in Q1 2026.
- 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.